Stability of Pro-Gastrin-Releasing Peptide in Serum versus Plasma

被引:23
|
作者
Yoshimura, Toru [1 ]
Fujita, Kenju [1 ]
Kawakami, Satoshi [1 ]
Takeda, Katsumichi [2 ]
Chan, Sabrina [3 ]
Beligere, Gangamani [4 ]
Dowell, Barry [3 ]
机构
[1] Abbott Japan, Div Diagnost, Diagnost Res, Chiba 2702214, Japan
[2] Abbott Japan, Div Diagnost, Res & Dev, Chiba 2702214, Japan
[3] Abbott Labs, Div Diagnost, Diagnost Res, Lake Cty, IL USA
[4] Abbott Labs, Div Diagnost, Diagnost R&D Proc Design, Lake Cty, IL USA
关键词
Pro-gastrin-releasing peptide; Small cell lung cancer; Thrombin;
D O I
10.1159/000152940
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aims: Although serum assays for pro-gastrin-releasing peptide (ProGRP) assays have been commercially available in Japan for several years, the stability of ProGRP in serum and plasma has not been well documented. We investigated the stability of ProGRP in serum and plasma with fresh and stored (frozen) specimens, as well as the cause of the observed instability in serum. Methods/Results: ProGRP concentrations in fresh serum were decreased by 6-28% after room temperature storage for 2 h and by 8-32% after 2-8 degrees C storage for 24 h. The average change in ProGRP concentrations in fresh plasma was within +/-10% of baseline for more than 4 h at room temperature and for more than 24 h at 2-8 degrees C. The incubation of a serine protease, thrombin (activated blood coagulation factor II), in a buffer solution containing ProGRP caused decreases in ProGRP concentrations. Following the addition of phenylmethylsulfonyl fluoride, a serine protease inhibitor, to serum, the serum stability for ProGRP was similar to that in plasma. ProGRP is significantly more stable in plasma than in serum. We speculate that thrombin in serum is one of the factors that inactivate ProGRP in serum by proteolysis of the ProGRP antigen. Conclusion: The use of plasma samples for ProGRP may improve the clinical reliability of this marker by minimizing preanalytical changes in ProGRP concentrations. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码:224 / 230
页数:7
相关论文
共 50 条
  • [1] Stability of Pro-gastrin releasing peptide in serum and plasma
    Yoshimura, Toru
    Fujita, Kenju
    Kawakami, Satoshi
    Kitahara, Maya
    Dowell, Barry
    TUMOR BIOLOGY, 2007, 28 : 109 - 109
  • [2] Clinical Application of Pro-Gastrin-Releasing Peptide
    Fang, Lili
    Huang, Zhongqiang
    Lin, Yongzhi
    Fu, Jianguo
    Liang, Xianming
    Liu, Fan
    CLINICAL LABORATORY, 2018, 64 (7-8) : 1259 - 1268
  • [3] Plasma Pro-gastrin-releasing peptide in lung cancer: prospective study
    Nisman, B.
    Nechustan, H.
    Biran, H.
    Ramu, N.
    Peretz, T.
    TUMOR BIOLOGY, 2012, 33 : 91 - 92
  • [4] Evaluation of chemiluminescent immunoassay quantitative detection for pro-gastrin-releasing peptide (ProGRP) in serum and plasma
    Cheng, Yizhuang
    He, Jing
    Zhang, Liping
    Chen, Xiufa
    Ou, Saiying
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019,
  • [5] Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction
    Kamata, K
    Uchida, M
    Takeuchi, Y
    Takahashi, E
    Sato, N
    Miyake, Y
    Okubo, M
    Kodama, T
    Yamaguchi, K
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (07) : 1267 - 1270
  • [6] Serum pro-gastrin-releasing peptide (31-98) in prostatic diseases
    Yashi, M
    Ishikawa, S
    Tokue, A
    UROLOGY, 2003, 62 (01) : 198 - 199
  • [7] A New Method for Determining Pro-Gastrin-Releasing Peptide
    Ohrvik, A.
    Olsson, M.
    Dahlen, U.
    Nilsson, O.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A113 - A113
  • [8] Automated Immunoassay for Pro-gastrin-releasing Peptide (ProGRP)
    Kobayashi, Eiji
    Kinukawa, Hideki
    Komori, Makoto
    Sakurai, Yousuke
    Iizuka, Masayuki
    Saegusa, Haruhisa
    Yoshimura, Toru
    Fujita, Kenju
    Dowell, Barry
    TUMOR BIOLOGY, 2008, 29 : 72 - 72
  • [9] Pro-gastrin-releasing peptide in patients with benign and malignant diseases
    Molina, R
    Auge, JM
    Alicarte, J
    Filella, X
    Viñolas, N
    Ballesta, AM
    TUMOR BIOLOGY, 2004, 25 (1-2) : 56 - 61
  • [10] Serum pro-gastrin-releasing peptide (31-98) in prostatic diseases - Reply
    Nagakawa, O
    UROLOGY, 2003, 62 (01) : 199 - 199